UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2012	Dec. 31, 2011
Current Assets
Cash	$ 131,723,186	$ 89,411,835
Short-term investment	2,727,509	0
Accounts receivable, net of allowance for doubtful accounts	14,961,521	16,757,368
Inventories	68,243,398	71,338,590
Other receivables	1,574,434	2,594,461
Prepayments and prepaid expenses	2,557,452	1,591,696
Deferred tax assets	1,905,210	1,999,563
Total Current Assets	223,692,710	183,693,513
Property, plant and equipment, net	39,153,534	40,546,539
Intangible assets, net	4,279,035	6,520,671
Land use rights, net	5,838,420	5,487,343
Prepayments and deposits for property, plant and equipment	9,391,850	4,287,492
Receivable related to land use right	13,202,220	0
Equity method investment	10,066,951	8,357,017
Total Assets	305,624,720	248,892,575
Current liabilities
Short-term bank loans	11,081,000	11,018,000
Accounts payable	3,922,947	4,996,463
Due to related parties	4,047,780	3,319,938
Other payables and accrued expenses	25,583,002	30,661,794
Advance from customers	3,941,270	4,365,523
Advance from customers - a related party	0	486,602
Income tax payable	5,921,081	5,373,633
Other taxes payable	2,322,662	2,189,913
Derivative liabilities - warrants	0	5,410,419
Total Current Liabilities	56,819,742	67,822,285
Other payable	343,821	343,477
Deferred tax liabilities	1,074,380	1,685,772
Total Liabilities	58,237,943	69,851,534
Stockholders' Equity
Common stock: par value $.0001; 100,000,000 shares authorized; 26,568,625 and 25,601,125 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively	2,657	2,560
Additional paid-in capital	60,173,625	48,838,311
Retained earnings	113,334,038	73,920,811
Accumulated other comprehensive income	13,654,977	12,750,682
Total stockholders' equity attributable to China Biologic Products, Inc.	187,165,297	135,512,364
Noncontrolling interest	60,221,480	43,528,677
Total Equity	247,386,777	179,041,041
Commitments and contingencies	0	0
Total Liabilities and Equity	$ 305,624,720	$ 248,892,575